What should I pay attention to when using sparsentan? Frequently asked questions from patients when taking medications

Sparsentan (Sparsentan, Sparsentan) is a new dual receptor antagonist that mainly blocks angiotensin II at the same time. Type 1 receptor (AT1) and endothelinA receptor (ETA), thereby reducing proteinuria and delaying the deterioration of renal function. Currently, sparsentane is mainly used to treat rare types of chronic kidney disease, such as focal segmental glomerulosclerosis (FSGS) and IgA nephropathy. Although the drug has shown good efficacy and safety in clinical studies, there are still many precautions and common problems that patients need to pay attention to during actual use.

Before using sparsentan, it must be evaluated by a professional doctor to ensure that the patient's indications are clear. This drug is suitable for patients with persistent proteinuria and diagnosed FSGS or IgA kidney disease, especially when conventional treatments (such as ACEI or ARB) are ineffective. However, not all patients with proteinuria can use sparsentan. If the patient has special conditions such as severe hypotension, liver insufficiency, or is pregnant, it may not be suitable for use. In addition, basic renal function, blood pressure, electrolytes and liver function tests need to be carried out before starting medication for comparison and monitoring during subsequent treatment.

Regular monitoring of kidney function, liver function and electrolyte levels is required during medication. As a drug that affects glomerular filtration function, sparsentan may cause an increase in serum creatinine or worsening of renal function in some patients, especially when combined with other underlying renal diseases or when diuretics are used at the same time. In addition, the drug may also affect liver metabolism, and some patients may experience elevated transaminases during treatment. Therefore, it is recommended to test liver function once a month at the beginning of medication, and then extend it to once every 3 months depending on the situation. Elevation of potassium ions is also an adverse reaction that requires vigilance, especially when combined with other drugs that affect kidney function (such as ACEI/ARB). Close attention should be paid to serum potassium levels.

Sparsentan has the potential to cause hypotension, particularly during initial use or during concomitant use of diuretics. If patients experience symptoms of dizziness, fatigue, or syncope, they should report it to their doctor immediately, who will evaluate whether the dose needs to be adjusted or the medication needs to be suspended. To reduce the risk of hypotension, it is recommended to gradually discontinue or reduce the dose of diuretics several days before starting sparsentan and to avoid strenuous exercise or rapid standing after taking the drug.

In female patients, attention must also be paid to contraception. Sparsentan may have toxic effects on the fetus, so women of childbearing potential must take effective contraceptive measures during treatment and rule out pregnancy before starting treatment. If the patient plans to become pregnant or becomes pregnant unexpectedly while taking the drug, he should stop taking the drug immediately and seek medical help. At the same time, it is also recommended to avoid using this drug during breastfeeding to prevent the drug from having adverse effects on the baby through milk.

Regarding common questions from patients, many people are worried that the drug will not be effective when they first start using sparsentane, especially when the decrease in proteinuria is not significant in the short term. It should be pointed out that sparsentan is a drug that acts on the process of chronic kidney disease. Its treatment goal is not only to reduce proteinuria in the short term, but also to delay the decline of renal function in the long term. Therefore, the treatment cycle is usually longer, and patients should be patient and review their indicators on time. Another common problem is price and accessibility. Sparsentane is currently not on the market in my country. If patients want to use it, they need to purchase it through overseas channels. The price is relatively high. The original drug may cost tens of thousands of yuan, while the price of generic drugs (such as the Laos version) is relatively low, but it still needs to be used under the guidance of a doctor.

In short, sparsentan is a promising new drug in the field of chronic kidney disease treatment, but its use requires strict compliance with medical instructions, regular testing of relevant indicators, and attention to monitoring of potential adverse reactions. If the patient has any discomfort during the medication, he should inform the doctor as soon as possible for treatment. At the same time, since the drug has not yet been launched in China, access channels, medication safety and affordability also need to be comprehensively considered. It is recommended that patients make prudent decisions after evaluating the pros and cons under the guidance of professional doctors.

Reference materials:https://www.sparsentan.com/